Lifestance Health Group (LFST) AI Stock Analysis

• Market Cap: $2.47B
• Dividend Yield: N/A
• Average Volume (3M): 2.60M
• Price to Earnings (P/E): 281.2
• Beta (1Y): 0.65
• Revenue Growth: 13.39%
• EPS Growth: 90.55%
• Country: US
• Employees: 7,535
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.01
• Shares Outstanding: 389,783,200
• 10 Day Avg. Volume: 2,838,522
• 30 Day Avg. Volume: 2,601,749
• PEG Ratio: -2.34
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 1.91
• P/FCF Ratio: 24.70
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 1.69
• Enterprise Value/Gross Profit: 5.56
• Enterprise Value/Ebitda: 30.63
• 1Y Price Target: $10.14
• Price Target Upside: 60.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 0.07
• Revenue Forecast (FY): $1.64B

• Rating: 59 Neutral
• Price Target: $7.00 ▲(10.58% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is driven primarily by improving financial performance and a constructive earnings outlook with continued growth and margin expansion. These positives are tempered by weak technical momentum and a very high P/E that reduces valuation support.

Positive Factors

Revenue Growth & Guidance

Clear multi-year top-line momentum and explicit 2026 guidance (~15% growth) provide durable revenue visibility. Management’s mid‑teens longer‑term target implies scalable demand and a runway to invest in capacity and margin expansion rather than relying on short‑lived patchwork gains.

Clinician Scale & Utilization

A growing clinician network plus rising visits per clinician indicates structurally higher capacity and utilization. Scale in clinicians and visit throughput supports sustainable revenue growth, improves unit economics, and creates a durable lever for expanding margins as fixed overhead dilutes across more billable sessions.

Improved Cash Generation & Balance Sheet

Operating and free cash flow turned meaningfully positive while leverage declined, strengthening financial flexibility. This durable cash generation supports disciplined capital allocation (buybacks, tuck‑ins, reinvestment) and reduces refinancing/liquidity risk as the company scales clinics and technology investments.

Negative Factors

Thin Profitability

Profitability is an early inflection but remains razor‑thin after several loss years. With net and EBIT margins near breakeven, modest adverse moves in reimbursement, utilization, or staffing costs could erase gains. The short track record of sustained profits raises execution risk for durable margin expansion.

Clinician Recruiting & Labor Pressure

Structural clinician scarcity and local labor competition drive ongoing cost pressure and incentive spend. Sustained need for hiring bonuses, SBC or cash substitutes increases operating cost per visit and complicates consistent clinician supply, limiting reliable capacity growth and pressuring margins over time.

EHR Transition & New Center Dilution

A multi‑year enterprise EHR rollout plus a batch of lower‑margin new centers creates persistent execution and cash‑use risk. Implementation delays or productivity setbacks can be structural headwinds, diluting center margins and slowing the realization of anticipated scale and AI-driven efficiency gains.

Lifestance Health Group Business Overview & Revenue Model

Company Description

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona.

How the Company Makes Money

LifeStance primarily makes money by providing outpatient mental health services and billing third-party payors and patients for those services. The core revenue stream is patient service revenue generated from clinician-delivered visits, including (1) psychotherapy sessions provided by therapists (e.g., psychologists, licensed clinical social workers, counselors) and (2) psychiatric services such as diagnostic evaluations and ongoing medication management provided by psychiatrists and advanced practice providers. Services are reimbursed largely through commercial insurance plans and government programs (e.g., Medicare and Medicaid), with additional revenue from patient out-of-pocket payments (copays, deductibles, and self-pay). Revenue is generally driven by appointment volume (visit count), payer reimbursement rates/fee schedules and contracted rates, the mix of services (therapy vs. psychiatry and initial evaluations vs. follow-ups), the mix of payers (commercial vs. government vs. self-pay), clinician capacity and utilization (hiring/retention and filled schedules), and the proportion of services delivered via telehealth versus in-person. LifeStance also relies on being in-network with many insurers; payer contracting and credentialing can materially affect how quickly clinicians can bill and the effective reimbursement collected. If requested: null

Lifestance Health Group Financial Statement Overview

Summary

A clear turnaround is underway: revenue expanded strongly since 2020, 2025 returned to profitability, leverage improved (lower debt-to-equity), and operating/free cash flow strengthened. The offset is decelerating growth and still-thin margins, with limited history proving the durability of the profitability inflection.

Income Statement

Revenue has grown consistently from $377M (2020) to $1.424B (2025), but growth has decelerated materially (from ~77% in 2020 to ~4% in 2025). Profitability has improved sharply: the company moved from large losses in 2021–2024 to positive results in 2025 (net margin ~0.7% and EBIT margin ~1.7%), suggesting an inflection point. The key weakness is that margins remain thin and recent history includes multiple years of meaningful losses, so the durability of the turnaround is not yet proven.

Balance Sheet

Leverage looks manageable and improving: debt-to-equity declined from ~0.34–0.36 (2023–2024) to ~0.13 in 2025, supported by a sizable equity base ($1.52B) versus debt ($194M). Total assets are relatively stable around ~$2.1–$2.2B, indicating balance sheet scale without heavy recent expansion. The main weakness is that returns on equity have been weak/negative for several years and only recently turned slightly positive (~0.6% in 2025), which implies limited profitability relative to capital.

Cash Flow

Cash generation improved meaningfully: operating cash flow rose from negative in 2023 to $107M (2024) and $146M (2025), and free cash flow turned solidly positive ($146M in 2025) with strong growth (~22% in 2025). Cash flow has generally tracked earnings better recently, but a caution flag is that operating cash flow still covers only about 58% of debt in 2025 (improved vs. prior years, but not robust), and cash flow was volatile earlier in the period with negative free cash flow in multiple years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.42B	1.25B	1.06B	859.54M	667.51M
Gross Profit	406.35M	402.40M	302.10M	237.02M	201.51M
EBITDA	78.78M	39.87M	-104.93M	-143.60M	-240.06M
Net Income	9.66M	-57.44M	-186.26M	-215.56M	-307.20M
Balance Sheet
Total Assets	2.20B	2.12B	2.11B	2.17B	1.93B
Cash, Cash Equivalents and Short-Term Investments	248.64M	154.57M	78.82M	108.62M	148.03M
Total Debt	194.10M	485.19M	511.04M	478.83M	158.74M
Total Liabilities	682.92M	672.01M	681.04M	655.15M	382.08M
Stockholders Equity	1.52B	1.45B	1.43B	1.52B	1.55B
Cash Flow
Free Cash Flow	110.03M	85.69M	-57.40M	-26.47M	-85.07M
Operating Cash Flow	146.15M	107.26M	-16.88M	52.79M	9.42M
Investing Cash Flow	-36.13M	-21.57M	-60.34M	-139.46M	-194.08M
Financing Cash Flow	-15.96M	-9.95M	47.43M	47.26M	313.86M

Lifestance Health Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFST, the sentiment is Negative. The current price of 6.33 is below the 20-day moving average (MA) of 7.00, below the 50-day MA of 7.08, and above the 200-day MA of 5.86, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 32.40 is Neutral, neither overbought nor oversold. The STOCH value of 8.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFST.

Lifestance Health Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	78 Outperform	$2.51B	17.67	9.94%	1.80%	23.74%	-18.99%
SEM	62 Neutral	$2.02B	12.54	5.57%	1.69%	-22.96%	-59.35%
LFST	59 Neutral	$2.47B	281.23	0.65%	―	13.39%	90.55%
BKD	58 Neutral	$3.31B	-9.62	-523.78%	―	3.93%	-42.22%
ACHC	55 Neutral	$2.17B	-1.17	-39.42%	―	4.58%	-61.50%
AVAH	52 Neutral	$1.45B	32.50	-135.90%	―	15.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Lifestance Health Group Corporate Events

LifeStance Health Appoints Lisa Miller as Chief Operating Officer

On March 10, 2026, LifeStance Health Group, Inc. promoted Lisa Miller, 52, to Chief Operating Officer and Principal Operating Officer, elevating her from her previous roles leading practice operations since September 2022 and drawing on her prior executive experience at Invo Healthcare. The move strengthens LifeStance’s operational leadership as Miller’s compensation package, including a $485,000 base salary, performance-based annual bonus, and a three-year vesting equity award mix of time- and performance-based restricted stock units, is designed to align her incentives with the company’s long-term performance and growth goals.

The most recent analyst rating on (LFST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Lifestance Health Group stock, see the LFST Stock Forecast page.

Lifestance Health Announces Secondary Offering and Share Repurchase

On February 25, 2026, LifeStance Health Group, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and certain selling stockholders for an underwritten secondary offering of 25,000,000 shares of its common stock, under an existing shelf registration filed in May 2024. All shares were sold by the selling stockholders, and the company did not receive any proceeds from the offering, which closed on March 2, 2026.

As part of the transaction, LifeStance agreed to repurchase 7,000,000 of the offered shares from the underwriter at the same price paid to the selling stockholders, with the underwriter receiving no compensation on the repurchased portion. The deal effectively shifts ownership among existing investors while allowing the company to reduce its public float by the repurchased shares, with legal opinions on the shares provided by Ropes & Gray LLP.

The most recent analyst rating on (LFST) stock is a Buy with a $8.50 price target. To see the full list of analyst forecasts on Lifestance Health Group stock, see the LFST Stock Forecast page.

LifeStance Health Guides 2026 Growth, Announces Buyback Program

On February 25, 2026, LifeStance Health Group reported that fourth-quarter 2025 revenue rose 17% year over year to $382.2 million and full-year revenue climbed 14% to $1.42 billion, driven by an expanded clinician base, higher visit volumes and improved productivity. The company swung to positive net income of $11.7 million in the quarter and $9.7 million for 2025, expanded Adjusted EBITDA by 49% in the quarter to $48.8 million, generated $146.2 million in operating cash flow for the year and ended 2025 with a solid cash position and moderate net debt.

Management issued 2026 guidance calling for further growth to $1.615 billion–$1.655 billion in revenue and higher Center Margin and Adjusted EBITDA, signaling confidence in continued operating leverage. The board also authorized a $100 million share repurchase program, underscoring LifeStance’s improved profitability and cash generation and suggesting a stronger capital return profile that could enhance shareholder value while the company continues to invest in long-term expansion.

The most recent analyst rating on (LFST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lifestance Health Group stock, see the LFST Stock Forecast page.